Revenio Group Oyj: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Revenio Group Oyj Issues FY 2013 Net Sales and Operating Profit Guidance
Revenio Group Oyj announced that in continuing operations, net sales and operating profit excluding non-recurring items (EBIT) are expected to see year-on-year growth in the fiscal year (FY) 2013. According to I/B/E/S Estimates, analysts on average are expecting the Company to report FY 2013 net sales of EUR 28.62 million and FY 2013 EBIT of EUR 5.26 million.
Latest Key Developments in Advanced
- Bacterin International Holdings gives Q2 2014 guidance below analysts' estimates
- Boston Scientific Corp receives FDA approval for REBEL Platinum Chromium Coronary Stent System
- Syneron Medical receives China CFDA clearance for elure advanced skin brightening lotion
- WaferGen Bio-systems, Inc announces appointment of Ivan Trifunovich as chairman
- Share this
- Digg this